CN1721442A - 产生改变的免疫原性应答的蛋白质及制备和应用这种蛋白质的方法 - Google Patents

产生改变的免疫原性应答的蛋白质及制备和应用这种蛋白质的方法 Download PDF

Info

Publication number
CN1721442A
CN1721442A CNA2005100836207A CN200510083620A CN1721442A CN 1721442 A CN1721442 A CN 1721442A CN A2005100836207 A CNA2005100836207 A CN A2005100836207A CN 200510083620 A CN200510083620 A CN 200510083620A CN 1721442 A CN1721442 A CN 1721442A
Authority
CN
China
Prior art keywords
ala
gly
ser
val
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005100836207A
Other languages
English (en)
Chinese (zh)
Inventor
D·A·埃斯特尔
F·A·哈丁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Danisco US Inc
Original Assignee
Genencor International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genencor International Inc filed Critical Genencor International Inc
Publication of CN1721442A publication Critical patent/CN1721442A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
    • C12N9/2437—Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 3.2.1.150)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01004—Cellulase (3.2.1.4), i.e. endo-1,4-beta-glucanase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
CNA2005100836207A 2000-02-08 2001-01-22 产生改变的免疫原性应答的蛋白质及制备和应用这种蛋白质的方法 Pending CN1721442A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/500,135 2000-02-08
US09/500,135 US6838269B1 (en) 1998-04-15 2000-02-08 Proteins producing an altered immunogenic response and methods of making and using the same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN01804669A Division CN1418253A (zh) 2000-02-08 2001-01-22 产生改变的免疫原性应答的蛋白质及制备和应用这种蛋白质的方法

Publications (1)

Publication Number Publication Date
CN1721442A true CN1721442A (zh) 2006-01-18

Family

ID=23988185

Family Applications (3)

Application Number Title Priority Date Filing Date
CNA2005100836207A Pending CN1721442A (zh) 2000-02-08 2001-01-22 产生改变的免疫原性应答的蛋白质及制备和应用这种蛋白质的方法
CN01804669A Pending CN1418253A (zh) 2000-02-08 2001-01-22 产生改变的免疫原性应答的蛋白质及制备和应用这种蛋白质的方法
CN2010102215832A Expired - Fee Related CN101906464B (zh) 2000-02-08 2001-01-22 产生改变的免疫原性应答的蛋白质及制备和应用这种蛋白质的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN01804669A Pending CN1418253A (zh) 2000-02-08 2001-01-22 产生改变的免疫原性应答的蛋白质及制备和应用这种蛋白质的方法
CN2010102215832A Expired - Fee Related CN101906464B (zh) 2000-02-08 2001-01-22 产生改变的免疫原性应答的蛋白质及制备和应用这种蛋白质的方法

Country Status (12)

Country Link
US (1) US6838269B1 (enExample)
EP (1) EP1254240B1 (enExample)
JP (1) JP5112587B2 (enExample)
KR (1) KR20020073582A (enExample)
CN (3) CN1721442A (enExample)
AR (1) AR027358A1 (enExample)
AT (1) ATE355377T1 (enExample)
AU (1) AU3651201A (enExample)
CA (1) CA2399019A1 (enExample)
DE (1) DE60126915T2 (enExample)
DK (1) DK1254240T3 (enExample)
WO (1) WO2001059130A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6967080B1 (en) * 1990-12-05 2005-11-22 Novozymes A/S Proteins with changed epitopes and methods for the production thereof
US6936249B1 (en) * 1998-04-15 2005-08-30 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
CA2249648A1 (en) * 1998-11-04 2000-05-04 Nabil G. Seidah Mammalian subtilisin/kexin isozyme ski-1: a proprotein convertase with a unique cleavage specificity
JP2004532618A (ja) * 2001-02-06 2004-10-28 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 低減された免疫原性を有する修飾されたレプチン
WO2003057246A1 (en) * 2001-12-31 2003-07-17 Genencor International, Inc. Proteases producing an altered immunological response and methods of making and using the same
EP2287321B1 (en) * 2002-01-16 2014-08-13 Danisco US Inc. Multiply-substituted protease variants
AU2003213580A1 (en) * 2002-02-26 2003-09-09 Genencor International, Inc. Subtilisin carlsberg proteins with reduced immunogenicity
CN101597601B (zh) * 2002-06-26 2013-06-05 诺维信公司 具有改变的免疫原性的枯草杆菌酶和枯草杆菌酶变体
WO2004078960A1 (en) * 2003-02-26 2004-09-16 Genencor International, Inc. Amylases producing an altered immunogenic response and methods of making and using the same
EP2500423B1 (en) * 2003-02-26 2015-06-17 Danisco US Inc. Amylases producing an altered immunogenic response and methods of making and using the same
KR20160064249A (ko) 2005-03-23 2016-06-07 글락소스미스클라인 바이오로지칼즈 에스.에이. Ｃｄ4 ｔ－세포 및/또는 개선된 ｂ－메모리 세포 반응을 유도하는 인플루엔자 바이러스 및 수중유 에멀젼 애주번트의 용도
WO2006113209A1 (en) * 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
PL2043682T3 (pl) 2006-07-17 2014-09-30 Glaxosmithkline Biologicals Sa Szczepionka przeciw grypie
JP5230397B2 (ja) * 2008-12-18 2013-07-10 独立行政法人科学技術振興機構 抗膜貫通型タンパク質抗体の抗原結合部位を決定する方法
US8937159B2 (en) 2009-12-16 2015-01-20 Abbvie Biotherapeutics Inc. Anti-HER2 antibodies and their uses
EP3164486B1 (en) 2014-07-04 2020-05-13 Novozymes A/S Subtilase variants and polynucleotides encoding same
CN106661566A (zh) 2014-07-04 2017-05-10 诺维信公司 枯草杆菌酶变体以及编码它们的多核苷酸
EP3464582A1 (en) * 2016-06-03 2019-04-10 Novozymes A/S Subtilase variants and polynucleotides encoding same

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR7904209A (pt) 1978-07-04 1980-06-17 Novo Industri As Preparacao de protease adequada para mistura a composicoes de lavagem processo para preparatease cepa de b licheniformis e composicao de lavagem
US5700676A (en) * 1984-05-29 1997-12-23 Genencor International Inc. Modified subtilisins having amino acid alterations
WO1992010755A1 (en) 1990-12-05 1992-06-25 Novo Nordisk A/S Proteins with changed epitopes and methods for the production thereof
US5593877A (en) * 1993-03-11 1997-01-14 The Rockefeller University Nucleic acid and recombinant production of vespid venom hyaluronidase
DK96493D0 (da) 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
JPH10509324A (ja) 1994-11-24 1998-09-14 ノボ ノルディスク アクティーゼルスカブ 抑制されたアレルゲン性を有するポリペプチドの製造のための方法
US5951980A (en) * 1995-01-06 1999-09-14 Leuven Research & Development Vzw Identification, production and use of new staphylokinase derivatives with reduced immunogenicity
BR9608149B1 (pt) 1995-05-05 2012-01-24 processos para efetuar mutação no dna que codifica uma enzima de subtilase ou sua pré- ou pré-pró-enzima e para a manufatura de uma enzima de subtilase mutante.
US5837517A (en) * 1995-05-05 1998-11-17 Novo Nordisk A/S Protease variants and compositions
CN1273589C (zh) 1996-02-15 2006-09-06 诺沃奇梅兹有限公司 多肽缀合
WO1998020116A1 (en) 1996-11-04 1998-05-14 Novo Nordisk A/S Subtilase variants and compositions
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
WO1999006061A1 (en) 1997-07-29 1999-02-11 The Administrators Of The Tulane Educational Fund Prediction, detection, and design of t cell epitopes
US6495136B1 (en) * 1998-03-26 2002-12-17 The Procter & Gamble Company Proteases having modified amino acid sequences conjugated to addition moieties
US6835550B1 (en) 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
US6642011B2 (en) * 1998-04-15 2003-11-04 Genencor International, Inc. Human protease and use of such protease for pharmaceutical applications and for reducing the allergenicity of non-human proteins
CA2238660A1 (en) 1998-05-22 1999-11-22 Janet Chantler Gene sequences of rubella virus associated with attenuation
ES2278463T3 (es) 1998-12-08 2007-08-01 Biovation Limited Metodo para reducir la inmunogenicidad de proteinas.

Also Published As

Publication number Publication date
CN101906464B (zh) 2013-03-27
EP1254240B1 (en) 2007-02-28
WO2001059130A2 (en) 2001-08-16
CN101906464A (zh) 2010-12-08
KR20020073582A (ko) 2002-09-27
CA2399019A1 (en) 2001-08-16
DK1254240T3 (da) 2007-07-02
JP2004500088A (ja) 2004-01-08
AR027358A1 (es) 2003-03-26
DE60126915T2 (de) 2007-11-15
CN1418253A (zh) 2003-05-14
AU3651201A (en) 2001-08-20
US6838269B1 (en) 2005-01-04
ATE355377T1 (de) 2006-03-15
JP5112587B2 (ja) 2013-01-09
DE60126915D1 (de) 2007-04-12
WO2001059130A3 (en) 2002-03-07
EP1254240A2 (en) 2002-11-06

Similar Documents

Publication Publication Date Title
CN1721442A (zh) 产生改变的免疫原性应答的蛋白质及制备和应用这种蛋白质的方法
CN1662649A (zh) 具有改变的免疫原性的枯草杆菌酶和枯草杆菌酶变体
US6835550B1 (en) Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
CN1784490A (zh) 变体枯草杆菌蛋白酶(枯草杆菌酶)
CN1163507C (zh) 蛋白酶缀合物
CN1512998A (zh) 具有改变的免疫原性反应的蛋白质及制备和使用该蛋白质的方法
CN1133068A (zh) 枯草杆菌蛋白酶变异体
CN1871351A (zh) 一种新的真菌蛋白及其编码核酸
CN1110323A (zh) 新多肽和编码它们的脱氧核糖核酸
CN1226174A (zh) 应用蛋白酶抑制剂预防或降低骨的吸收
US6642011B2 (en) Human protease and use of such protease for pharmaceutical applications and for reducing the allergenicity of non-human proteins
CN1399677A (zh) 在确定表位区有氨基酸取代的枯草杆菌蛋白酶变体
CN1942584A (zh) 蛋白酶变体
CN1445236A (zh) 促进毛发生长的寡肽
CN1768137A (zh) 枯草杆菌酶
CN1324404A (zh) 新型肿瘤抗原蛋白sart－3及其肿瘤抗原肽
US20060024764A1 (en) Proteins producing an altered immunogenic response and methods of making the same
CN1877336A (zh) 鉴定生物药物中与免疫原性相关表位的方法
CN1969042A (zh) 具有改变的免疫原性的枯草杆菌酶变体
CN1158639A (zh) 编码与白介素-1β转换酶相关的人Tx和Ty蛋白的DNA序列
CN1639571A (zh) 将蛋白质相对免疫原性进行分级的基于群体的评估方法和手段
CN1745169A (zh) 产生改变的免疫原应答的淀粉酶及其制备和使用方法
CN101065398A (zh) Hsp60的肽和apl型衍生物及药物组合物
CN1426469A (zh) 具有一个或多个d－氨基酸取代的酶变体
CA2424720C (en) Proteins producing an altered immunogenic response and methods of making and using the same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20060118